PNC Financial Services Group Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

PNC Financial Services Group Inc. lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,021 shares of the medical equipment provider’s stock after purchasing an additional 1,286 shares during the period. PNC Financial Services Group Inc.’s holdings in Lantheus were worth $990,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Signaturefd LLC grew its holdings in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus during the 3rd quarter worth about $51,000. Finally, Nkcfo LLC purchased a new stake in Lantheus during the 2nd quarter worth about $47,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Up 0.8 %

NASDAQ:LNTH opened at $90.27 on Thursday. The company has a market cap of $6.28 billion, a P/E ratio of 15.02 and a beta of 0.51. The firm’s 50 day moving average is $102.48 and its two-hundred day moving average is $97.13. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Analyst Ratings Changes

A number of brokerages have recently commented on LNTH. JMP Securities lowered their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Finally, Truist Financial reissued a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.